The urine microRNA profile may help monitor post-transplant renal graft function

Kidney International

Volumn 85, Issue 2, 2014, Pages 439-449

  Maluf, Daniel G ^a   Dumur, Catherine I ^b   Suh, Jihee L ^a   Scian, Mariano J ^a   King, Anne L ^b   Cathro, Helen ^c   Lee, Jae K ^c   Gehrau, Ricardo C ^a   Brayman, Kenneth L ^a   Gallon, Lorenzo ^d   Mas, Valeria R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

biomarkers; chronic allograft dysfunction; microRNA; urinary cell pellets

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 106B; MICRORNA 125B; MICRORNA 140 3P; MICRORNA 184; MICRORNA 185; MICRORNA 193B; MICRORNA 200B; MICRORNA 203; MICRORNA 23B; MICRORNA 30A; MICRORNA 345; MICRORNA 375; MICRORNA 423 5P; MICRORNA 425; MICRORNA 451; MICRORNA 486 5P; MICRORNA 513A 5P; MICRORNA 575; MICRORNA 92A; MICRORNA 99A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE ONTOLOGY; DNA MICROARRAY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; URINALYSIS; VALIDATION STUDY;

ADULT; AGED; ATROPHY; BIOPSY; CASE-CONTROL STUDIES; FEMALE; FIBROSIS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC TESTING; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MICRORNAS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; URINALYSIS; YOUNG ADULT;

EID: 84895902220     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.338     Document Type: Article

References (62)

1. Al-Awwa IA, Hariharan S, First MR. Importance of allograft biopsy in renal transplant recipients: Correlation between clinical and histological diagnosis. Am J Kidney Dis 1998; 31(Suppl 1): S15-S18
2. John R, Herzenberg AM. Our approach to a renal transplant biopsy. J Clin Pathol 2010; 63: 26-37
3. Kozakowski N, Regele H. Biopsy diagnostics in renal allograft rejection: From histomorphology to biological function. Transpl Int 2009; 22: 945-953
4. Mannon RB, Kirk AD. Beyond histology: Novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 2006; 1: 358-366
5. Gourishankar S, Leduc R, Connett J et al. Pathological and clinical characterization of the troubled transplant Data from the DeKAF study. Am J Transplant 2010; 10: 324-330
6. Rush D. Can protocol biopsy better inform our choices in renal transplantation? Transplant Proc 2009; 41(Suppl): S6-S8
7. Lezaic V, Naumovic R, Marinkovic J et al. Donor kidney glomerular filtration rate and post-Transplant graft function. Am J Transplant 2004; 4: 1669-1674
8. Bargnoux AS, Servel AC, Pieroni L et al. Accuracy of GFR predictive equations in renal transplantation: Validation of a new turbidimetric cystatin C assay on Architect c8000. Biology of renal function and renal failure working group. Clin Biochem 2012; 45: 151-153
9. Buron F, Hadj-Aissa A, Dubourg L et al. Estimating glomerular filtration rate in kidney transplant recipients: Performance over time of four creatinine-based formulas. Transplantation 2011; 92: 1005-1011
10. Eriksen BO, Mathisen UD, Melsom T et al. The role of cystatin C in improving GFR estimation in the general population. Am J Kidney Dis 2012; 59: 32-40
11. Delanaye P, Mariat C, Moranne O et al. Estimating glomerular filtration rate in 2012: Which adding value for the CKD-EPI equation? Nephrol Ther 2012; 8: 199-205
12. Diamantidis CJ, Seliger SL, Zhan M et al. A varying patient safety profile between Black and nonBlack adults with decreased estimated GFR. Am J Kidney Dis. 2012; 60: 47-53
13. Kwong YT, Stevens LA, Selvin E et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010; 56: 39-49
14. Ju W, Smith S, Kretzler M. Genomic biomarkers for chronic kidney disease. Transl Res 2012; 159: 290-302
15. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: A review. Kidney Int 2011; 80: 806-821
16. Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: A review. Semin Immunopathol 2011; 33: 211-218
17. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012; 21: 410-416
18. Kong YW, Ferland-McCollough D, Jackson TJ et al. MicroRNAs in cancer management. Lancet Oncol 2012; 13: E249-e258
19. Beltrami C, Clayton A, Phillips AO et al. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans 2012; 40: 875-879
20. Matheson A, Willcox MD, Flanagan J et al. Urinary biomarkers involved in type 2 diabetes: A review. Diabetes Metab Res Rev 2010; 26: 150-171
21. Caubet C, Lacroix C, Decramer S et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol 2010; 25: 27-35
22. Afaneh C, Muthukumar T, Lubetzky M et al. Urinary cell levels of mRNA for OX40,OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 2010; 90: 1381-1387
23. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-Allograft recipients. N Engl J Med 2005; 353: 2342-2351
24. Dadhania D, Snopkowski C, Ding R et al. Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 2010; 90: 189-197
25. Mas V, Maluf D, Archer K et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007; 83: 448-457
26. Mas VR, Mas LA, Archer KJ et al. Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med 2007; 13: 315-324
27. Sui W, Dai Y, Huang Y et al. Microarray analysis of microRNA expression in acute rejection after renal transplantation. Transpl Immunol 2008; 19: 81-85
28. Anglicheau D, Sharma VK, Ding R et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009; 106: 5330-5335
29. Lorenzen JM, Volkmann I, Fiedler J et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11: 2221-2227
30. Scian MJ, Maluf DG, David KG et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011; 11: 2110-2122
31. Sales G, Coppe A, Bisognin A et al. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Am J Transplant 2010; 38: W352-W359
32. Bisognin A, Sales G, Coppe A et al. MAGIA2: From miRNA and genes expression data integrative analysis to microRNA-Transcription factor mixed regulatory circuits (2012 update). Nucleic Acids Res 2012; 40: W13-W21
33. He W, Tan RJ, Li Y et al. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/b-catenin activity in CKD. J Am Soc Nephrol 2012; 23: 294-304
34. Szeto CC, Chow KM, Lai KB et al. mRNA expression of target genes in the urinary sediment as a noninvasive prognostic indicator of CKD. Am J Kidney Dis 2006; 47: 578-586
35. Wang G, Lai FM, Lai KB et al. Messenger RNA expression of podocyteassociated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract 2007; 106: C169-c179
36. Scian MJ, Maluf DG, Archer KJ et al. Gene expression changes are associated with loss of kidney graft function and interstitial fibrosis and tubular atrophy: Diagnosis versus prediction. Transplantation 2011; 91: 657-665
37. Shannon P, Markiel A, Ozier O et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504
38. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1
39. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760
40. Chandrasekaran K, Karolina DS, Sepramaniam S et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 2012; 81: 617-627
41. Bhatt K, Mi QS, Dong Z. MicroRNAs in kidneys: Biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol 2011; 300: F602-F610
42. Kato M, Natarajan R. MicroRNA circuits in transforming growth factor-b actions and diabetic nephropathy. Semin Nephrol 2012; 32: 253-260
43. Li JY, Yong TY, Michael MZ et al. Review: The role of microRNAs in kidney disease. Nephrology (Carlton) 2010; 15: 599-608
44. Elias S, Mandelboim O. Battle of the midgets: Innate microRNA networking. RNA Biol 2012; 9: 792-798
45. Liston A, Papadopoulou AS, Danso-Abeam D et al. MicroRNA-29 in the adaptive immune system: Setting the threshold. Cell Mol Life Sci 2012; 69: 3533-3541
46. Hu R, O'Connell RM. MicroRNA control in the development of systemic autoimmunity. Arthritis Res Ther 2013; 15: 202
47. Merkerova M, Belickova M, Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 2008; 81: 304-310
48. Chen CZ, Li L, Lodish HF et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86
49. Huang B, Zhao J, Lei Z et al. MiR-142-3p restricts cAMP production in CD4CD25- T cells and CD4CD25 TREG cells by targeting AC9 mRNA. EMBO Rep 2009; 10: 180-185
50. Medrano S, Monteagudo MC, Sequeira-Lopez ML et al. Two microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its smooth muscle phenotype. Am J Physiol Renal Physiol 2012; 302: F29-F37
51. Tili E, Michaille JJ, Cimino A et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-Alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089
52. Tsitsiou E, Lindsay MA. MicroRNAs and the immune response. Curr Opin Pharmacol 2009; 9: 514-520
53. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs: Novel regulators in skin inflammation. Clin Exp Dermatol 2008; 33: 312-315
54. Malumbres R, Sarosiek KA, Cubedo E et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-3764
55. Chaudhuri AA, So AY, Sinha N et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011; 187: 5062-5068
56. Primo MN, Bak RO, Schibler B et al. Regulation of pro-inflammatory cytokines TNFa and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012; 60: 741-748
57. Maluf DG, Mas VR, Archer KJ et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med 2008; 14: 276-285
58. Tang O, Chen X, Shen S et al. MiRNA-200b represses transforming growth factor beta1-induced EMT and fibronectin expression in kidney proximal tubular cells. Am J Physiol Renal Physiol 2013; 304: F1266-F1273
59. Xiong M, Jiang L, Zhou Y et al. The miR-200 family regulates TGF-b1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012; 302: F369-F379
60. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
61. Noma H, Matsui S. The optimal discovery procedure in multiple significance testing: Anempirical Bayes approach. Stat Med 2012; 31: 165-176
62. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: Z289-Z300 Diseases